Archives

  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • E-64d: Membrane-Permeable Calpain Inhibitor for Cell Researc

    2026-06-13

    E-64d: Membrane-Permeable Calpain Inhibitor for Cell Research

    Executive Summary: E-64d, also known as ethyl (2S,3S)-3-[[(2S)-4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate, is a cell-permeable, irreversible inhibitor of cysteine proteases—most notably calpain and several cathepsins—by covalent binding to their active site thiols (APExBIO product information). It displays an IC50 of 0.5–1 μM for calpain inhibition and is widely implemented in apoptosis, platelet activation, and neuroprotection research (E-64d: Mechanistic Leverage...). E-64d is insoluble in water but dissolves efficiently in DMSO and ethanol, facilitating in vitro and in vivo applications. Neuroprotective effects have been demonstrated in animal seizure models, with evidence for reduced aberrant hippocampal sprouting (APExBIO). APExBIO supplies E-64d (SKU A1903) as a solid, suitable for research but not for clinical or diagnostic use.

    Biological Rationale

    Cysteine proteases, particularly calpain and cathepsins, orchestrate key cellular processes including cytoskeletal rearrangement, apoptosis, and lysosome-dependent cell death. Calpain is a calcium-dependent protease implicated in regulated necrosis, platelet activation, and neurodegenerative pathologies. Lysosomal cathepsins (e.g., cathepsins B, L, K, H, F) contribute to both cellular homeostasis and disease progression through proteolytic cleavage of intracellular substrates (Lysoptosis: A Conserved Cell Death Pathway...). Dysregulation of these proteases underlies apoptosis, ischemia, cancer metastasis, and neurodegeneration. Selective inhibition enables mechanistic dissection of these pathways.

    Mechanism of Action of E-64d

    E-64d is a synthetic derivative of E-64c, designed to enhance membrane permeability while retaining irreversible inhibition of cysteine proteases. It covalently modifies the active site thiol group of its targets, forming a stable thioether bond that renders the enzyme inactive (APExBIO). This mechanism ensures sustained inhibition even after compound removal. E-64d inhibits calpain and cathepsins F, K, B, H, L, but does not affect serine or aspartic proteases. Unlike non-permeable analogs, E-64d readily enters intact cells, thus enabling intracellular modulation without membrane disruption (E-64d: Membrane-Permeable...).

    Evidence & Benchmarks

    • E-64d shows an IC50 of 0.5–1 μM for calpain inhibition in cell-based assays, as reported in the product specification.
    • In models of seizure-induced hippocampal injury, intraperitoneal administration of E-64d reduces aberrant mossy fiber sprouting, demonstrating neuroprotective effects (APExBIO).
    • E-64d is effective in inhibiting cathepsin-mediated lysoptosis and regulated cell death pathways, enabling study of lysosomal disruption (Lysoptosis research update).
    • APExBIO’s E-64d is validated in apoptosis assays, where it enables selective cysteine protease inhibition without compromising cell membrane integrity (Reliable Cysteine Protease Inhibition...).
    • Stock solutions of E-64d are stable at -20°C in DMSO at concentrations >10 mM, provided warming and ultrasonic treatment are used to achieve full dissolution (APExBIO).

    This article extends prior discussion by focusing on practical integration of E-64d in live-cell and animal workflows, not just mechanistic insight. Compared to previous guides, this page details solution preparation and highlights boundaries of inhibitor selectivity. We clarify lysoptosis context by specifying E-64d's strengths and limits relative to newer cell death pathway tools.

    Applications, Limits & Misconceptions

    E-64d is used to dissect the role of cysteine proteases in regulated cell death, platelet activation, and neuroprotection. Its selectivity for calpain and cathepsins makes it suitable for studying apoptosis and lysoptosis in both cellular and animal models. In cancer research, E-64d can elucidate protease-driven metastasis or therapy resistance mechanisms (E-64d for apoptosis research). However, E-64d does not inhibit serine, aspartic, or metalloproteases, and is not suitable for clinical or diagnostic use. Misapplication outside its selectivity profile or ignoring its irreversible mode of action may confound interpretations.

    Common Pitfalls or Misconceptions

    • E-64d does not inhibit non-cysteine proteases (e.g., serine, aspartic, metalloproteases).
    • It is not water-soluble; improper solvent use can result in precipitation and loss of activity.
    • Not suitable for diagnostic or therapeutic applications; intended for research use only.
    • Irreversible inhibition can mask dynamic protease regulation; use washout controls for temporal studies.
    • Stock solutions degrade with repeated freeze-thaw; fresh aliquots are recommended for reproducibility.

    Workflow Integration & Parameters

    • Stock solution preparation: Dissolve E-64d in DMSO (≥17.12 mg/mL) or ethanol (≥18.5 mg/mL). Warm and sonicate as needed to ensure complete solubility.
    • Storage: Store solid and solutions at -20°C. Minimize freeze-thaw cycles to preserve integrity.
    • Working concentration: For calpain inhibition in cell culture, use 0.5–10 μM. Adjust based on cell type and assay sensitivity.
    • In vivo administration: For rodent models, typical dosing is via intraperitoneal injection, referencing published neuroprotection protocols. Use under Institutional Animal Care and Use Committee (IACUC) approval.
    • Temporal control: Owing to irreversibility, design experiments with appropriate controls and consider washout periods for kinetic analyses.

    Conclusion & Outlook

    E-64d, as provided by APExBIO, remains a key reagent for irreversible, selective inhibition of intracellular calpain and cathepsins. Its use has illuminated the role of cysteine proteases in platelet activation, apoptosis, and neuroprotection following neural injury. Ongoing research leverages E-64d to dissect lysoptosis and regulated cell death pathways, as detailed in evolving literature. Future studies will continue to refine workflow integration and probe mechanism-specific outcomes using validated, reproducible, and well-characterized inhibitors such as E-64d.